Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2015
- Source ID
- 10.1016/j.bbmt.2014.10.006
Entities
People
- Alison W. Loren
- Amir Steinberg
- Anne B. Warwick
- Bipin N Savani
- Christine N. Duncan
- David A. Jacobsohn
- David I. Marks
- David L. Porter
- Donna A. Wall
- Harry C. Schouten
- Haydar A. Frangoul
- Hillard M Lazarus
- Jack W. Hsu
- Jean-yves Cahn
- Joseph A. Pidala
- Kasiani C. Myers
- Kimberly A. Kasow
- Lolie C. Yu
- Maxim Norkin
- Mohamed L Sorror
- Nandita Khera
- Navneet S Majhail
- Paulette Mehta
- Rammurti T. Kamble
- Richard T. Maziarz
- Robert J. Hayashi
- Ruta Brazauskas
- Vijay Reddy
- Wael Saber
- William A. Wood
- Zhiwei Wang
Organizations
- ARIAD Pharmaceuticals
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- CellGenix (Germany)
- Children’s Leukemia Research Association
- Elevance Health, Inc.
- GSK
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)